10.1177/1758835919889001 - A phase II study of the efficacy and ...

This document has been corrected

A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma

10.1177/1758835919889001

Published Online: 2019-01-?

Journal: Therapeutic Advances in Medical Oncology•Publisher: SAGE Publications

Authors: Chia-Jui Yen•Guohong Han•Hongming Pan•Jianming Xu•Lu Hao•Luigi Manenti•Minshan Chen•Ralph Tiedt•Shukui Qin•Stephen Lam Chan•Su Pin Choo•Tawesak Tanwandee•Thomas Yau•Virote Sriuranpong•Wattana Sukeepaisarnjaroen•Wenjie Song•Yabing Guo•Yi Gu•Yongjian Sun•Zhenggang Ren•Zhong-Zhe Lin

This document has been corrected

A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma

10.1177/1758835919889001

Published Online: 2019-01-?

Journal: Therapeutic Advances in Medical Oncology

NOW

2024-08-03•Correction

Corrigendum to “A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma”

10.1177/17588359241264967